Glycated Albumin Assay Market by Product, Application (Prediabetes, Type 1 Diabetes, Type 2 Diabetes), End User

Description

List of Tables

[191 Pages Report] The Glycated Albumin Assay Market size was estimated at USD 217.29 million in 2023 and expected to reach USD 232.69 million in 2024, at a CAGR 7.51% to reach USD 360.92 million by 2030.

Global Glycated Albumin Assay Market

KEY MARKET STATISTICS
Base Year [2023]	USD 217.29 million
Estimated Year [2024]	USD 232.69 million
Forecast Year [2030]	USD 360.92 million
CAGR (%)	7.51%

Glycated albumin is a biomarker used for assessing and monitoring diabetes mellitus, reflecting shorter-term changes in blood glucose levels compared to other biomarkers such as glycated hemoglobin (HbA1c). The rising prevalence of diabetes and increasing public awareness about monitoring and controlling blood glucose raises need for accurate and reliable testing methods. However, reimbursement policies and regulatory frameworks in various countries may hinder the widespread use of glycated albumin assays. Nevertheless, expanding healthcare infrastructure in emerging economies provides greater access to advanced diagnostics tools such as glycated albumin assays, and research into novel biomarkers for glucose regulation is expected to create new avenues for growth within the glycated albumin assay market.

Regional Insights

The Americas has a significant landscape in the glycated albumin assay market owing to a substantial need for glycated albumin assay due to the high prevalence of diabetes in these countries. Additionally, countries have advanced healthcare systems that can support the adoption of innovative diagnostic tools such as glycated albumin assays. The growing aging population in Europe contributes significantly to the increasing demand for advanced diagnostics such as glycated albumin assays. EU countries have comprehensive healthcare systems that prioritize early detection of diseases such as diabetes, increasing the glycated albumin assay demand in the region. In the Middle East and Africa region, there has been a steady rise in lifestyle-related diseases, including diabetes, due to changing demographics and urbanization. Various programs, initiatives, and investments by legal authorities promoted the adoption of innovative diagnostic techniques in the region. The Asia Pacific market for glycated albumin assay is expanding rapidly due to the growing prevalence of diabetes, increasing research and development activities, and significant advancements in developing novel techniques for glycated albumin detection.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Glycated Albumin Assay Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Glycated Albumin Assay Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Glycated Albumin Assay Market, highlighting leading vendors and their innovative profiles. These include Abcam PLC, Abnova Corporation, Asahi Kasei Corporation, Beijing Strong Biotechnologies Inc., Cardinal Health Inc., Crystal Chem Inc., Diazyme Laboratories Inc., DxGen Corp., EKF Diagnostics Holdings PLC, Epinex Diagnostics Inc., Ethos Biosciences, Inc., FroggaBio Inc., Hymes Biotech, Laboratory Corporation of America Holdings, LifeSpan BioSciences, Inc., and Weldon Biotech Inc..

Market Segmentation & Coverage

This research report categorizes the Glycated Albumin Assay Market to forecast the revenues and analyze trends in each of the following sub-markets:

Product
- Animal Glycated Albumin Assay
- Human Glycated Albumin Assay
Application
- Prediabetes
- Type 1 Diabetes
- Type 2 Diabetes
End User
- Diabetic Care Centres
- Diagnostic Laboratories
- Hospitals & Clinics
Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam
- Europe, Middle East & Africa
  - Denmark
  - Egypt
  - Finland
  - France
  - Germany
  - Israel
  - Italy
  - Netherlands
  - Nigeria
  - Norway
  - Poland
  - Qatar
  - Russia
  - Saudi Arabia
  - South Africa
  - Spain
  - Sweden
  - Switzerland
  - Turkey
  - United Arab Emirates
  - United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Glycated Albumin Assay Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Glycated Albumin Assay Market?

3. What are the technology trends and regulatory frameworks in the Glycated Albumin Assay Market?

4. What is the market share of the leading vendors in the Glycated Albumin Assay Market?

5. Which modes and strategic moves are suitable for entering the Glycated Albumin Assay Market?

Product Code: MRR-A579C431592D

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. Glycated Albumin Assay Market, by Region

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Rising prevalence of diabetes worldwide
  - 5.1.1.2. Increased focus on preventive healthcare measures
  - 5.1.1.3. Favorable reimbursement policies for medical professionals
- 5.1.2. Restraints
  - 5.1.2.1. Lack of awareness about glycated albumin testing and high cost associated with assays
- 5.1.3. Opportunities
  - 5.1.3.1. Advancements in technology for improved assay methodologies with enhanced accuracy and sensitivity
  - 5.1.3.2. Government initiatives such as early screening programs for diabetes
- 5.1.4. Challenges
  - 5.1.4.1. Unavailability of standardized protocols across different laboratories leads to inconsistencies in results
5.2. Market Segmentation Analysis
- 5.2.1. Product: Increasing use of animal glycated albumin assay to understand disease mechanisms
- 5.2.2. Application: Significant adoption of glycated albumin assay for detection of type 1 diabetes owing to prevent health complications
- 5.2.3. End User: High usage of glycated albumin assay in diagnostic laboratories
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter's Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework

6. Glycated Albumin Assay Market, by Product

6.1. Introduction
6.2. Animal Glycated Albumin Assay
6.3. Human Glycated Albumin Assay

7. Glycated Albumin Assay Market, by Application

7.1. Introduction
7.2. Prediabetes
7.3. Type 1 Diabetes
7.4. Type 2 Diabetes

8. Glycated Albumin Assay Market, by End User

8.1. Introduction
8.2. Diabetic Care Centres
8.3. Diagnostic Laboratories
8.4. Hospitals & Clinics

9. Americas Glycated Albumin Assay Market

9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Glycated Albumin Assay Market

10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa Glycated Albumin Assay Market

11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape

12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player
- 12.3.1. Merger & Acquisition
  - 12.3.1.1. Sartorius Agrees to Acquire Albumedix

13. Competitive Portfolio

13.1. Key Company Profiles
- 13.1.1. Abcam PLC
- 13.1.2. Abnova Corporation
- 13.1.3. Asahi Kasei Corporation
- 13.1.4. Beijing Strong Biotechnologies Inc.
- 13.1.5. Cardinal Health Inc.
- 13.1.6. Crystal Chem Inc.
- 13.1.7. Diazyme Laboratories Inc.
- 13.1.8. DxGen Corp.
- 13.1.9. EKF Diagnostics Holdings PLC
- 13.1.10. Epinex Diagnostics Inc.
- 13.1.11. Ethos Biosciences, Inc.
- 13.1.12. FroggaBio Inc.
- 13.1.13. Hymes Biotech
- 13.1.14. Laboratory Corporation of America Holdings
- 13.1.15. LifeSpan BioSciences, Inc.
- 13.1.16. Weldon Biotech Inc.
13.2. Key Product Portfolio

14. Appendix

14.1. Discussion Guide
14.2. License & Pricing